PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 23, 2019JAMA Cardiology600 citationsOpen Access

Apolipoprotein B Particles and Cardiovascular Disease

View Full Paper
ASAllan D. SnidermanGTGeorge ThanassoulisTGTamara Glavinovic

Key Points

  • To evaluate how apolipoprotein B (apoB) integrates and enhances conventional lipid metrics to assess atherogenic cardiovascular risk.
  • Narrative synthesis examining apolipoprotein B biology and particle counts in relation to conventional lipid panels.
  • Evaluation of atherogenic risk quantification across apoB-containing lipoprotein fractions.
  • Apolipoprotein B consolidates and simplifies risk information provided across standard lipid measurements.
  • Measurement of apoB amplifies detection of total atherogenic particle burden driving cardiovascular disease.

Abstract

Apolipoprotein B unifies, amplifies, and simplifies the information from the conventional lipid markers as to the atherogenic risk attributable to the apoB lipoproteins.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sniderman et al. (2019) studied this question.

synapsesocial.com/papers/69d84e8cd2f7327e70ae2e3dhttps://doi.org/10.1001/jamacardio.2019.3780
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women2017 · 109 citations
  2. 2Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].1980 · 637 citations
  3. 3High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease.1988 · 107 citations
  4. 4Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins2012 · 806 citations
  5. 5A Test in Context: Lipoprotein(a)2017 · 1,150 citations